This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Centre National De La Recherche Scientifique, National Institute of Health and Medical Research, Université Nice Sophia Antipolis. Active years: 2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:


Years Active: 2015
Title: Mohsine Driowya: Innovator in Cancer Treatment
Introduction
Mohsine Driowya is a notable inventor based in Nice, France. He has made significant contributions to the field of cancer treatment through his innovative research and development of pharmaceutical compositions.
Latest Patents
Driowya holds a patent for "Acadesine derivatives, products and compositions including same, therapeutic uses thereof, and methods for synthesizing same." This patent describes Acadesine derivatives as a drug, particularly for the treatment of cancer, including chronic myeloid leukemia. The patent outlines the use of these derivatives in combination with at least one second active ingredient for simultaneous, separate, or sequential administration in cancer treatment. Additionally, it details a method for inhibiting in vitro cell proliferation by placing an in vitro cell in contact with the derivatives, along with methods for synthesizing these derivatives.
Career Highlights
Throughout his career, Mohsine Driowya has worked with esteemed institutions such as Université Nice Sophia Antipolis and the Centre National de la Recherche Scientifique. His work has focused on developing therapeutic solutions that address critical health challenges.
Collaborations
Driowya has collaborated with notable colleagues, including Rachid Benhida and Patrick Auberger, contributing to advancements in cancer research and treatment methodologies.
Conclusion
Mohsine Driowya's innovative work in developing Acadesine derivatives showcases his commitment to improving cancer treatment options. His contributions to pharmaceutical science are significant and continue to impact the field positively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile